The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
Steven P. Treon, Jorge J. Castillo, Alan P Skarbnik, Jacob D. Soumerai, Irene M. Ghobrial, Maria Luisa Guerrera, Kirsten Meid, Guang Yang
Abstract
Treon et al provide early clinical data supporting a theoretical rationale for continuing ibrutinib in patients receiving the drug during COVID-19 illness.
Topics & Concepts
IbrutinibBruton's tyrosine kinaseCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyInternal medicineIntensive care medicineLeukemiaChronic lymphocytic leukemiaInfectious disease (medical specialty)ReceptorDiseaseTyrosine kinaseChronic Lymphocytic Leukemia ResearchGalectins and Cancer BiologyPI3K/AKT/mTOR signaling in cancer